The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic fac...
Saved in:
Main Authors: | Arwa M. Amin, Lim Sheau Chin, Dzul Azri Mohamed Noor, Muhamad Ali SK Abdul Kader, Yuen Kah Hay, Baharudin Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Cardiology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2017/8062796 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The CYP2C19*1/*2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers
by: Yanti Nasyuhana Sani, et al.
Published: (2013-01-01) -
Pharmacometabolomics Enables Real-World Drug Metabolism Sciences
by: Fleur B. Nijdam, et al.
Published: (2025-01-01) -
Pharmacogenetics of Oral Antidiabetic Drugs
by: Matthijs L. Becker, et al.
Published: (2013-01-01) -
Pharmacogenetics of Chronic Pain and Its Treatment
by: Svatopluk Světlík, et al.
Published: (2013-01-01) -
Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
by: Amilton Dos Santos-Júnior, et al.
Published: (2016-01-01)